Related Experiment Video
Updated: May 10, 2025
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world
Bing Xie1, Nan Ye1, Guoqin Wang1
1Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Background:
The renal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been confirmed. However, SGLT2i may lead to an increase in serum creatine shortly after administration. This study explores the factors influencing this change and its impact on long-term renal function.
Methods:
We retrospectively studied patients starting SGLT2i treatment, classifying them into kidney function deterioration (RD) and non-deterioration (non-RD) groups based on three-month serum creatinine changes. Multivariate logistic regression identified factors influencing RD, and mixed-effects linear models evaluated eGFR slope changes.
Results:
A total of 544 patients were included, with 78 (14.3%) in the RD group and 466 (85.7%) in the non-RD group. Lower eGFR and serum albumin are independent risk factors for RD. With the decrease of eGFR by 10 mL/min/1.73㎡, the risk of RD increased by 42.3% (p < .001). With the decrease of serum albumin by 5 g/L, the risk of RD increased by 41.7% (p < .001). The maximum difference in eGFR between the RD and non-RD groups was 13.88 mL/min/1.73 m2 (95%CI, 9.99 to 17.78; p < .001) on two months. One year after medication, the difference in eGFR was not related to whether RD occurred (p ≥ .05). During the first three months post-medication, the difference in the eGFR slope between the two groups was 40.51 mL/min/1.73 m2 per year (95%CI, 27.43 to 53.60; p < .001). Over three years, the difference in the eGFR slope was 0.59 mL/min/1.73 m2 per year (95%CI, -0.69 to 1.88; p > .05).
Conclusions:
While some experiences an increase in serum creatine, there is no significant long-term difference in renal function between the two groups.
More Related Videos
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:27Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:23Dipeptidyl Peptidase 4 Inhibitors
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones